Managing Benign Esophageal Tumors: Leiomyomas and Lipomas

Benign esophageal tumours are uncommon, but they can create significant diagnostic uncertainty when dysphagia, chest discomfort or an incidental imaging finding raises concern for malignancy. Leiomyomas and lipomas are the two most frequently encountered benign mesenchymal lesions, although their behaviour and treatment requirements differ. Learn more about 筋萎縮におけるプロテアソーム系とオートファジー.

A careful assessment combines endoscopy, endoscopic ultrasound (EUS), cross-sectional imaging and, when appropriate, tissue sampling. The main goals are to define the lesion’s layer of origin, exclude cancer, relieve symptoms and avoid unnecessary major surgery.

The educational resources associated with the ISDE 2021 congress remain useful for reviewing specialist approaches to oesophageal disease; historical registration and congress information is available through the ISDE registration page. Management decisions should still reflect current Australian guidance, local expertise and the patient’s overall health.

Recognising Rare Submucosal Lesions

Leiomyomas usually arise from the muscularis propria and are composed of smooth muscle. They are commonly found in the middle or lower third of the oesophagus and may appear as firm, rounded subepithelial bulges. Small lesions are often silent, while larger growths can cause progressive dysphagia, food sticking or retrosternal pressure.

Lipomas contain mature adipose tissue and tend to be soft, smooth and yellowish beneath intact mucosa. Their characteristic “pillow sign” on endoscopy can be helpful, but it is not sufficient to rule out other subepithelial masses. A large lipoma may cause swallowing difficulty, regurgitation or an aspiration risk.

Confirming Diagnosis Safely

Endoscopy identifies the mucosal surface and permits assessment of ulceration, bleeding or narrowing. EUS is particularly valuable because it shows whether a lesion originates in the submucosa or muscularis propria and can distinguish a fatty lesion from a solid smooth-muscle mass. CT of the chest may help define size, extension and relationships with nearby structures.

Routine superficial biopsies often provide little information because the abnormal tissue lies beneath normal mucosa. EUS-guided sampling may be considered when imaging is atypical or malignancy remains plausible, although sampling a firm leiomyoma can be technically difficult. Pathology and immunohistochemistry help distinguish leiomyoma from gastrointestinal stromal tumour and other rare neoplasms. Research-minded clinicians may also find broader discussions of cellular proteostasis pathways useful when considering how tissue biology informs future diagnostic work.

When Observation Is Appropriate

An asymptomatic, confidently characterised lesion can often be monitored rather than removed. Surveillance intervals should be individualised according to size, imaging features, symptoms and diagnostic confidence. Repeat endoscopy or EUS is more appropriate than relying on symptoms alone, since slow enlargement may be clinically subtle.

Observation is less suitable when there is rapid growth, mucosal ulceration, unexplained weight loss, progressive dysphagia, anaemia or uncertainty about the diagnosis. A multidisciplinary review involving gastroenterology, upper gastrointestinal surgery, radiology and pathology can prevent both under-treatment and unnecessary intervention.

Endoscopic Treatment Options

Endoscopic resection may be appropriate for selected lipomas, especially those that are small or pedunculated and clearly confined to the submucosa. Techniques include snare removal, endoscopic mucosal resection and endoscopic submucosal dissection. Larger lesions require careful planning because bleeding, perforation and incomplete excision are possible.

For leiomyomas arising from the muscularis propria, endoscopic submucosal tunnelling or endoscopic full-thickness approaches may be considered in experienced centres. These methods can avoid thoracic surgery, but they require advanced equipment, anaesthetic support and a team familiar with closure techniques and post-procedure monitoring.

Surgical Management And Recovery

Surgery remains important for large, deeply embedded, symptomatic or diagnostically uncertain leiomyomas. Enucleation is commonly preferred when feasible because it preserves the oesophageal lumen and avoids oesophagectomy. The approach may be open, laparoscopic, thoracoscopic or robotic, depending on tumour location, size and institutional expertise.

After treatment, patients are monitored for leak, bleeding, infection, reflux and swallowing problems. Dietary progression is gradual, and follow-up endoscopy or imaging may be arranged when resection was incomplete or the original diagnosis was uncertain. Persistent dysphagia should prompt reassessment rather than being attributed automatically to postoperative recovery.

Practical Points For Australian Teams

In Australia, referral pathways vary between metropolitan and regional services. A patient in Sydney or Melbourne may access EUS and advanced endoscopy through a tertiary hospital, whereas someone in regional Queensland, Western Australia or the Northern Territory may need coordinated travel and telehealth review.

Useful clinical priorities include:

• Confirm the lesion’s layer of origin before selecting treatment.
• Record symptoms, growth pattern, size and imaging characteristics.
• Discuss surveillance versus intervention in a multidisciplinary setting.
• Explain risks, alternatives and expected dietary recovery clearly.

Local practicalities also affect timing and access. Public hospital waiting lists, private health insurance rules and Medicare-funded consultations can influence where assessment occurs. Australian clinicians should check current Therapeutic Goods Administration requirements for devices and follow state or territory legislation governing consent, credentialling and hospital procedures.

Patient habits matter as well. Regular tea, coffee, alcohol consumption and swallowing tablets without enough water may amplify symptoms in a narrowed oesophagus, although these factors do not cause most benign tumours. Advice should be personalised rather than based on broad dietary restrictions.

Comparing Treatment Pathways

The most suitable option depends on diagnostic certainty, lesion depth, symptoms and local expertise. A small, typical lipoma may need no treatment, while a large muscular lesion with progressive dysphagia warrants specialist intervention.

A practical pathway is to document the lesion carefully, confirm its anatomical origin, assess the patient’s swallowing function and then match treatment intensity to symptoms and risk. For Australian practice, early coordination between the referring clinician, endoscopist, radiologist and upper gastrointestinal surgeon helps minimise delays and keeps the final decision patient-centred.